Janssen Pharmaceutical Inc.
1125 Trenton-Harbourton Road
382 articles with Janssen Pharmaceutical Inc.
Janssen Demonstrates Strong Commitment To Research And Development Of Therapies For Inflammatory Bowel Diseases With Nine Data Presentations At ACG 2020
Final, Five-Year Results of Long-Term Extension Study of Clinical Response and Remission of STELARA® (ustekinumab) in Patients with Moderate-to-Severe Crohn's Disease to be Featured in Oral Presentation
New First-in-Class Phase 3 Data Demonstrate TREMFYA® (guselkumab) Maintained Skin Clearance Rates Through Nearly 5 Years of Continuous Use in Adult Patients with Moderate to Severe Plaque Psoriasis
Data from VOYAGE 1 open-label, long-term extension study show sustained efficacy response rates at week 252 and no new safety signals
TREMFYA® (guselkumab) Induces Clinical and Endoscopic Improvements in Patients with Moderately to Severely Active Crohn's Disease based on Interim Results from Phase 2 Study
Interim analyses from GALAXI 1 study presented as an oral presentation at the United European Gastroenterology Week Virtual 2020 Congress
STELARA® (ustekinumab) Five-Year Results Presented from Long-term Extension Study of Clinical Response and Remission in Patients with Moderate to Severe Crohn's Disease
Final results of IM-UNITI study presented as an oral presentation at United European Gastroenterology Week Virtual 2020 Congress
Janssen Submits New Drug Application (NDA) to U.S. FDA for UPTRAVI® (selexipag) Injection for Intravenous Use to Treat Pulmonary Arterial Hypertension (PAH)
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a New Drug Application to the U.S. FDA for UPTRAVI® as an injection for intravenous use for the treatment of pulmonary arterial hypertension in adults with WHO functional class II–III, who are currently prescribed oral UPTRAVI but are temporarily unable to take oral therapy.
Grand River Aseptic Manufacturing (GRAM) inked a deal with Janssen Pharmaceutical, a Johnson & Johnson company, to support the manufacturing of Janssen’s COVID-19 vaccine candidate.
9/28/2020The European Society of Medical Oncology (ESMO) Virtual Congress 2020 was last weekend and the beginning of the week, which resulted in numerous clinical trial announcements. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 25, 2020.
Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen's COVID-19 Vaccine Candidate
First participants dosed in Phase 3 trial (ENSEMBLE) evaluating safety and efficacy of Janssen's COVID-19 vaccine candidate, JNJ-78436735, also known as Ad26.COV2.S
The European Society for Medical Oncology (ESMO) Virtual Congress 2020 was this weekend, with numerous companies presenting clinical trial data and updates.
9/21/2020It was a fairly busy week for clinical trial announcements, with some important and interesting news about COVID-19 treatments and vaccines, as well as numerous stories about non-COVID-19 studies.
Janssen Presents Findings from Global, Multi-Center Trial Examining Amivantamab in Combination with Lazertinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer
Phase 1b study shows bispecific antibody amivantamab and third-generation tyrosine kinase inhibitor (TKI) lazertinib achieved a 100 percent overall response rate in treatment-naïve EGFR-mutated NSCLC patient cohort
Janssen Highlights Impact of Multiple Sclerosis-Related Fatigue with Real-World Study Data Presentation at MSVirtual2020 and Global Patient Survey
Poster Presentation Shares New Data on the Symptoms and Impacts of Fatigue Using a New Disease-Specific Scale Global Patient Survey Reveals Approximately Two-Thirds of Multiple Sclerosis Patients Experience Fatigue on a Daily Basis
Janssen Submits Application Seeking U.S. FDA Approval of DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) for the Treatment of Patients with Light Chain (AL) Amyloidosis
Application is based on positive results from the Phase 3 ANDROMEDA study evaluating the efficacy and safety of combination therapy with DARZALEX FASPRO™
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 4, 2020.
Janssen to Present Latest Research in Multiple Sclerosis at MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting
Data Showcase Promising Safety and Efficacy for Investigational Multiple Sclerosis Therapy and Importance of Addressing Fatigue Symptoms
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that it has made a strategic decision to discontinue the development of pimodivir, an investigational antiviral treatment for influenza A infection. This decision is based on recent results from pre-planned interim analyses of the pimodivir Phase 3
Janssen Pharmaceutical of Johnson & Johnson made a strategic call to halt development of pimodivir, an antiviral treatment for influenza A.
Arrowhead and Collaborator Janssen Present Phase 2 Clinical Data on Investigational Hepatitis B Therapeutic JNJ-3989 at The Digital Liver Congress
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the presentation of Phase 2 clinical data from the AROHBV1001 phase 1/2 study on a double combination of JNJ-3989 (formerly ARO-HBV) and a nucleos(t)ide analog (NA) with collaborator Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson. The data are being presented in an oral presentation at The Digital Internat
U.S. FDA Approves New DARZALEX® (daratumumab)-Based Combination Regimen for Patients with Relapsed/Refractory Multiple Myeloma
Approval broadens DARZALEX label to include fifth treatment option in the relapsed/refractory setting and represents the eighth approved indication for DARZALEX [20-August-2020] HORSHAM, Pa. , Aug. 20, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of DARZALEX ® (